Literature DB >> 18196605

Mechanisms of inherited cancer susceptibility.

Shirley Hodgson1.   

Abstract

A small proportion of many cancers are due to inherited mutations in genes, which result in a high risk to the individual of developing specific cancers. There are several classes of genes that may be involved: tumour suppressor genes, oncogenes, genes encoding proteins involved in DNA repair and cell cycle control, and genes involved in stimulating the angiogenic pathway. Alterations in susceptibility to cancer may also be due to variations in genes involved in carcinogen metabolism. This review discusses examples of some of these genes and the associated clinical conditions caused by the inheritance of mutations in such genes.

Entities:  

Mesh：

Year:  2008        PMID： 18196605      PMCID： PMC2170461          DOI： 10.1631/jzus.B073001

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN： 1673-1581            Impact factor:   3.066


  21 in total

1.  Prophylactic mastectomy in carriers of BRCA mutations.

Authors:  S Narod
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Authors:  A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  Am J Hum Genet       Date:  2003-04-03       Impact factor: 11.025

3.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

Review 4.  The tumor spectrum in the Lynch syndrome.

Authors:  Patrice Watson; Bronson Riley
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Variation in BRCA1 cancer risks by mutation position.

Authors:  Deborah Thompson; Douglas Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-04       Impact factor: 4.254

6.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

7.  MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.

Authors:  H F Vasen; A Stormorken; F H Menko; F M Nagengast; J H Kleibeuker; G Griffioen; B G Taal; P Moller; J T Wijnen
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

8.  Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH.

Authors:  Julian R Sampson; Sunil Dolwani; Sian Jones; Diana Eccles; Anthony Ellis; D Gareth Evans; Ian Frayling; Sheila Jordan; Eamonn R Maher; Tony Mak; Julie Maynard; Francesca Pigatto; Joan Shaw; Jeremy P Cheadle
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

9.  Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study.

Authors:  Jae-Gahb Park; Duck-Woo Kim; Chang Won Hong; Byung-Ho Nam; Young-Kyoung Shin; Sung-Hye Hong; Il-Jin Kim; Seok-Byung Lim; Melyssa Aronson; Marie Luise Bisgaard; Gregor J Brown; John Burn; Elizabeth Chow; Peggy Conrad; Fiona Douglas; Malcolm Dunlop; James Ford; Marc S Greenblatt; Jarvinen Heikki; Karl Heinimann; Elly L Lynch; Finlay Macrae; Wendy C McKinnon; Gabriela Möeslein; Benedito Mauro Rossi; Paul Rozen; Lyn Schofield; Carlos Vaccaro; Hans Vasen; Mary Velthuizen; Alessandra Viel; Juul Wijnen
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

Review 10.  BRCA1: mechanisms of inactivation and implications for management of patients.

Authors:  Richard D Kennedy; Jennifer E Quinn; Patrick G Johnston; D Paul Harkin
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321
View more
  9 in total

Review 1.  Genomics of adult and pediatric solid tumors.

Authors:  Zahraa Rahal; Farah Abdulhai; Humam Kadara; Raya Saab
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 2.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

3.  MiR-339 and especially miR-766 reactivate the expression of tumor suppressor genes in colorectal cancer cell lines through DNA methyltransferase 3B gene inhibition.

Authors:  Ali Afgar; Pezhman Fard-Esfahani; Amirhosein Mehrtash; Kayhan Azadmanesh; Farnaz Khodarahmi; Mahdis Ghadir; Ladan Teimoori-Toolabi
Journal:  Cancer Biol Ther       Date:  2016-09-26       Impact factor: 4.742

Review 4.  Pancreatic cancer actionable genes in precision medicine and personalized surgery.

Authors:  Juehua Yu; Shi-He Liu; Robbi Sanchez; John Nemunaitis; Enrique Rozengurt; F Charles Brunicardi
Journal:  Surgeon       Date:  2016-06-28       Impact factor: 2.392

Review 5.  Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection.

Authors:  Phillip N Gray; Charles L M Dunlop; Aaron M Elliott
Journal:  Cancers (Basel)       Date:  2015-07-17       Impact factor: 6.639

Review 6.  Multilocus Inherited Neoplasia Allele Syndrome (MINAS): an update.

Authors:  Anthony McGuigan; James Whitworth; Avgi Andreou; Timothy Hearn; Marc Tischkowitz; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2022-01-04       Impact factor: 4.246

7.  TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.

Authors:  Phillip N Gray; Huy Vuong; Pei Tsai; Hsaio-Mei Lu; Wenbo Mu; Vickie Hsuan; Jayne Hoo; Swati Shah; Lisa Uyeda; Susanne Fox; Harshil Patel; Mike Janicek; Sandra Brown; Lavinia Dobrea; Lawrence Wagman; Elizabeth Plimack; Ranee Mehra; Erica A Golemis; Marijo Bilusic; Matthew Zibelman; Aaron Elliott
Journal:  Oncotarget       Date:  2016-10-18

8.  Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts.

Authors:  Rachel M Jones; Phillip E Melton; Mark Pinese; Alexander J Rea; Evan Ingley; Mandy L Ballinger; David J Wood; David M Thomas; Eric K Moses
Journal:  BMC Med Genet       Date:  2019-05-03       Impact factor: 2.103

9.  Determination of Pathogenicity of Breast Cancer 1 Gene Variants using the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines.

Authors:  Angela Brown; Mansour Zamanpoor; Donald R Love; Debra O Prosser
Journal:  Sultan Qaboos Univ Med J       Date:  2019-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.